Tesofensine Dosage Guide: Protocol, Benefits, Side Effects & Weight Loss Support

Tesofensine

Tesofensine is a non-peptide oral compound originally studied for neurological conditions and later investigated for its effects on appetite regulation, weight management, and metabolic health. It is being studied for its ability to influence satiety pathways and reduce food intake.

Important Distinction

Tesofensine is not a peptide.

It is typically discussed as an oral compound, not a reconstituted injectable.

Tesofensine is discussed as an oral compound and does not follow peptide-style reconstitution practices.

How It Works

Norepinephrine + Dopamine + Serotonin Reuptake Inhibition → Appetite ↓ → Satiety ↑ → Weight Loss Support

Tesofensine works by inhibiting presynaptic reuptake of norepinephrine, dopamine, and serotonin. This mechanism has been associated with reduced appetite, increased satiety, and lower food intake in research studies.

Tesofensine Research Framework

Appetite Suppression ↑ → Calorie Intake ↓ → Weight Loss Support

Weeks 1–4

Starting Phase

Dose0.25 mg

Weeks 5–12

Build Phase

Dose0.5 mg

Weeks 13–24

Extended Research Phase

Dose0.5 mg

Protocol Details

FrequencyOnce daily

TimingMorning preferred

Cycle Length12–24 weeks

Simple structure
Tesofensine has been studied in longer-duration research settings focused on appetite regulation and weight management. The goal is consistent appetite control over time, not short bursts of aggressive dosing.

Advanced Protocol

Higher Range

Higher Dose

Dose1.0 mg daily

Higher doses have shown greater weight-loss effects in research studies but were associated with increased side effects and reduced tolerability. Lower doses have generally shown a better balance between effectiveness and tolerability.

Administration & Monitoring

Oral use

Take once daily at a consistent time

Morning dosing is usually preferred

Monitor appetite, sleep, mood, heart rate, and blood pressure

Administration & Storage

FormOral compound

ReconstitutionNot required

Typical UseOnce daily oral dosing

Storage

Store in a cool, dry place

Protect from heat, moisture, and light

Research Duration & Reassessment

Research Phase → Appetite & Weight Response → Reassess → Continue or Pause

Research Duration Framework

Research Duration 12–24 weeks (commonly studied range)

Initial Dose Evaluation First 4–6 weeks

Commonly Studied Dose 0.5 mg daily

Reassessment Period

Off-Cycle Guidance No standardized break schedule established

Reassessment may be considered based on tolerability, response, and long-term sustainability.

Why Reassess Tesofensine?
Tesofensine affects neurotransmitter pathways involved in appetite regulation. Because long-term use requires evaluation of effectiveness and tolerability, reassessment allows review of appetite response, side effects, and whether continued use remains appropriate.

When to Stop or Pause Early

Sleep disruption becomes persistent

Heart rate or blood pressure changes occur

Mood or anxiety changes worsen

Appetite suppression becomes excessive or uncomfortable

Monitoring During Use

Appetite and portion control

Body weight and waist changes

Heart rate and blood pressure

Sleep quality, mood, and anxiety levels

Benefits

Appetite suppression observed in research studies

Improved satiety

Has been studied for effects on weight loss and body composition

May improve metabolic markers during successful weight loss

Potential Side Effects

Dry mouth

Nausea

Constipation or diarrhoea

Insomnia

Increased heart rate

Possible blood pressure or mood-related issues at higher doses

Important Notes

This is not a peptide and not an injectable blend

0.5 mg daily has been a commonly studied dose associated with a balance between weight-loss effects and tolerability

Higher doses may improve weight loss but reduce tolerability

Best used with nutrition and lifestyle support, not as a stand-alone solution

Important Disclaimer

Tesofensine is not FDA-approved and remains investigational in many markets. This content is for educational purposes only.

Research & References

Primary Research

• Astrup A, Madsbad S, Breum L, et al. Effect of Tesofensine on Bodyweight Loss, Body Composition, and Quality of Life in Obese Patients: A Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet. 2008.
• Hauser RA, Salin L, Juhel N, Konyago VL. Randomized Trial of the Triple Monoamine Reuptake Inhibitor NS 2330 (Tesofensine) in Early Parkinson's Disease. Movement Disorders. 2007.

Research Note: Tesofensine was originally developed for Parkinson's and Alzheimer's disease before its weight-loss effects were observed and it was repositioned as an investigational obesity therapy. It remains unapproved by the FDA and other major regulators for any indication.

Tesofensine Guide → Peptide Directory →